Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciclosporin is a calcineurin inhibitor immunosuppressant originally isolated from the fungus Tolypocladium inflatum. It acts by forming a complex with cyclophilin, which inhibits the phosphatase activity of calcineurin, leading to decreased production of inflammatory cytokines by T lymphocytes and suppression of immune responses. Ciclosporin is primarily used to prevent organ transplant rejection (kidney, liver, heart), and to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, nephrotic syndrome, eczema, ulcerative colitis, atopic dermatitis and keratoconjunctivitis sicca (dry eye) in ophthalmic formulations. It was first approved in 1983 and is available as oral capsules/solutions or intravenous infusions for systemic use; topical ophthalmic preparations are also widely used[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciclosporin.